Prelude Therapeutics Inc Ordinary Shares PRLD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRLD is a good fit for your portfolio.
News
-
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
-
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
-
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
-
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
Trading Information
- Previous Close Price
- $4.04
- Day Range
- $3.99–4.07
- 52-Week Range
- $1.66–6.89
- Bid/Ask
- $4.04 / $4.48
- Market Cap
- $223.53 Mil
- Volume/Avg
- 18,553 / 70,148
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 128
- Website
- https://www.preludetx.com
Comparables
Valuation
|
Metric
|
PRLD
|
PMVP
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.94 | 0.40 | 0.76 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PRLD
PMVP
VOR
Financial Strength
|
Metric
|
PRLD
|
PMVP
|
VOR
|
|---|---|---|---|
Quick Ratio | 10.67 | 14.47 | 8.81 |
Current Ratio | 10.79 | 14.78 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
PRLD
PMVP
VOR
Profitability
|
Metric
|
PRLD
|
PMVP
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −38.93% | −23.12% | −41.83% |
Return on Equity (Normalized) | −43.41% | −25.57% | −51.69% |
Return on Invested Capital (Normalized) | −42.59% | −27.79% | −47.03% |
Return on Assets
PRLD
PMVP
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hdvpdkskc | Fvgc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rtkhmjl | Wgdxs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tvgfvwwqy | Sgfzfk | $97.8 Bil | |
MRNA
| Moderna Inc | Lxktgqjm | Wxprs | $41.3 Bil | |
ARGX
| argenx SE ADR | Tsrnvgcg | Wtvkn | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vkrxmzbcd | Gwxqh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tblwwvsn | Lkbst | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lhtsbgmv | Cscmgjk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kmwhyrrtr | Yqjbft | $12.5 Bil | |
INCY
| Incyte Corp | Glcpbgbt | Xbvhcg | $11.6 Bil |